Maxwell Wealth Strategies Inc. Raises Holdings in Edwards Lifesciences Co. (NYSE:EW)

Maxwell Wealth Strategies Inc. increased its position in Edwards Lifesciences Co. (NYSE:EW) by 27.4% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 26,708 shares of the medical research company’s stock after acquiring an additional 5,742 shares during the quarter. Maxwell Wealth Strategies Inc.’s holdings in Edwards Lifesciences were worth $1,781,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in EW. Cetera Advisors LLC raised its position in shares of Edwards Lifesciences by 175.1% in the first quarter. Cetera Advisors LLC now owns 38,090 shares of the medical research company’s stock valued at $3,640,000 after purchasing an additional 24,242 shares during the period. BDF Gestion bought a new stake in Edwards Lifesciences during the 2nd quarter valued at $5,148,000. Tidal Investments LLC lifted its position in shares of Edwards Lifesciences by 54.7% during the first quarter. Tidal Investments LLC now owns 30,245 shares of the medical research company’s stock worth $2,890,000 after acquiring an additional 10,700 shares in the last quarter. Raymond James & Associates boosted its holdings in shares of Edwards Lifesciences by 2.8% in the second quarter. Raymond James & Associates now owns 1,825,230 shares of the medical research company’s stock worth $168,597,000 after acquiring an additional 50,124 shares during the period. Finally, AIA Group Ltd grew its position in shares of Edwards Lifesciences by 91.7% in the third quarter. AIA Group Ltd now owns 749,524 shares of the medical research company’s stock valued at $49,461,000 after purchasing an additional 358,556 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $67.76 on Friday. The firm has a market capitalization of $39.96 billion, a price-to-earnings ratio of 9.78, a PEG ratio of 3.74 and a beta of 1.12. The stock has a fifty day moving average of $67.44 and a 200 day moving average of $76.24. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, hitting the consensus estimate of $0.67. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The firm had revenue of $1.35 billion during the quarter, compared to analysts’ expectations of $1.57 billion. During the same period last year, the company posted $0.59 EPS. The company’s quarterly revenue was up 8.9% compared to the same quarter last year. As a group, research analysts expect that Edwards Lifesciences Co. will post 2.57 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Larry L. Wood sold 25,000 shares of the business’s stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the sale, the insider now owns 198,526 shares in the company, valued at approximately $13,084,848.66. The trade was a 11.18 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Daveen Chopra sold 1,250 shares of the company’s stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total transaction of $87,437.50. Following the completion of the sale, the vice president now directly owns 29,333 shares in the company, valued at $2,051,843.35. This represents a 4.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 41,250 shares of company stock worth $2,744,438. Company insiders own 1.29% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have weighed in on the company. The Goldman Sachs Group reduced their target price on Edwards Lifesciences from $107.00 to $91.00 and set a “buy” rating for the company in a report on Friday, July 26th. Wolfe Research raised shares of Edwards Lifesciences from an “underperform” rating to a “peer perform” rating in a report on Monday, July 29th. UBS Group decreased their price target on shares of Edwards Lifesciences from $90.00 to $75.00 and set a “neutral” rating on the stock in a report on Tuesday, September 10th. StockNews.com cut Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Thursday, July 25th. Finally, Morgan Stanley reiterated an “equal weight” rating and set a $70.00 price target on shares of Edwards Lifesciences in a research report on Friday, October 11th. Seventeen research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $75.67.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.